Easy-to-Implement Solution Helps Businesses,
Schools, and Other Organizations Reopen Responsibly and Stay Open
Safely During Infectious Illnesses
Masimo (NASDAQ: MASI) today announced the full market release of
Masimo SafetyNet-OPEN™, a web and mobile app solution that helps
businesses, schools, and other organizations screen, trace, and
manage users as they face COVID-19 and other infectious illnesses,
such as seasonal flu. SafetyNet-OPEN not only helps organizations
bring their people back to the workplace responsibly, but stay open
safely. Tailored for each organization’s safety protocols and
needs, SafetyNet-OPEN is capable of covering all stages of
back-to-work management, including risk screening, exposure contact
tracing, and recovery management.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210215005059/en/
Masimo SafetyNet-OPEN™ (Graphic: Business
Wire)
As a global leader in noninvasive patient monitoring
technologies and advanced connectivity and automation solutions,
Masimo is uniquely positioned to provide organizations with the
tools to assist them in staying open safely. Trusted by leading
hospitals to monitor more than 200 million patients each year,1
Masimo, in the first phase of the COVID-19 pandemic, developed the
Masimo SafetyNet™ remote patient management solution, now in use at
hospitals around the world, to help keep patients and frontline
workers safe. SafetyNet-OPEN builds on SafetyNet by scaling this
patient management to the level of entire organizations, no matter
the size. When escalation of care is needed, SafetyNet-OPEN can
even integrate clinical monitoring using Masimo SafetyNet, in
partnership with the organization’s health care provider or local
hospital.
Masimo SafetyNet-OPEN helps organizations identify those who are
most at risk of COVID-19 or other infectious viruses, trace
possible exposure to limit the spread of the virus, and monitor
users’ vital signs, including temperature, to help detect the onset
of fever, and arterial oxygen saturation, for signs of dangerous
deterioration. Based on answers to daily questions and
physiological data from connected monitoring devices, users receive
a personalized daily risk score, automating directives to stay
home, get tested, or seek treatment, configured according to each
organization’s safety protocols, back-to-work procedures, and
changing local health authority guidelines.
Flexible and versatile, the Masimo SafetyNet-OPEN system can be
augmented with additional components to offer more advanced
management of the organization’s users. To help screen potentially
infected users, results from on-site testing, implemented in
coordination with a trusted lab partner, can be securely stored and
taken into account in risk scoring and assessment. To improve
contact tracing, SafetyNet-OPEN can be customized with proximity
wristbands or with the Radius Tº™ wearable continuous thermometer
for both temperature measurement and proximity analysis, to help
track users’ exposure to those who may be at risk, including time
spent in close contact. And when care escalation may be needed, the
organization, in collaboration with a trusted clinical partner, can
easily incorporate vital signs data into SafetyNet-OPEN, to monitor
impacted users as their risk level rises or during recovery from
COVID-19, flu, or another illness. Data can be collected from the
Radius Tº continuous thermometer (to help track fever), the Radius
PPG™ wearable continuous pulse oximeter, and other monitoring
devices.
For businesses, schools, and organizations both large and small,
Masimo SafetyNet-OPEN is easy and fast to implement, with no
desktop software to install and with a dedicated Masimo support
team to ensure seamless rollout. A web-based workforce management
dashboard provides a clear picture of every team member’s status –
who’s at risk, who’s recovering, who’s cleared to work, proximity
violations, etc. – helping organizations efficiently and safely
manage their teams during COVID-19 and beyond. Every aspect, from
the daily risk-assessment questions, to the rules of the algorithm
that determines risk scores, to group assignments for contact
tracing, and more, can be easily customized. Furthermore,
SafetyNet-OPEN is designed to ensure user data is secure.
Dr. Richard Carmona, MD, MPH, 17th Surgeon General of the United
States and Distinguished Professor of Public Health at the
University of Arizona Mel and Enid Zuckerman College of Public
Health, said, “One of Masimo SafetyNet-OPEN’s greatest strengths is
its great versatility and customizability, which gives it enormous
potential to provide utility in so many settings. As a former
Surgeon General I can see tremendous application across a number of
federal agencies whose day-to-day operation and 24/7 capability we
all depend upon. At the University of Arizona, where I lead the
effort to safely reopen our campuses, we’ve been involved in
numerous initiatives examining how COVID-19 affects social groups –
for example, the effects of asymptomatic carriers, and how to
prevent ‘superspreader’ events. SafetyNet-OPEN’s risk assessment
and mitigation tools, which can be fine-tuned to accommodate our
evolving understanding of the disease, are ideal for better
understanding and coping with such a complex challenge.”
Claremont McKenna College President Hiram E. Chodosh, JD, said,
“We are grateful to Masimo for the pilot use of its SafetyNet-OPEN
tools, which we believe provide yet another important way for us to
strengthen the health and safety capabilities of our college campus
and the broader community.”
Dr. Mark Ferris, MSc, MRCGP, MFOM, Occupational Physician, UK,
commented, “Over the last year, we have gained considerable
knowledge about COVID-19 and how best to control it. It is clear
that to protect our colleagues or students, their families, our
workplaces, and the wider community, we need to combine as many
strategies as possible. These include the provision of accurate
information, physical distancing, masks, ventilation, hygiene
precautions, testing and monitoring, contact tracing, and supported
isolation. The Masimo SafetyNet-OPEN solution offers a vital way to
help organizations apply this combined strategy.”
Filmmaker Mark Kassen, Co-Founder and Executive Chairman of Like
Minded Media Ventures, added, “We are all anxious to get back to
work but without Masimo SafetyNet-OPEN, which we used during its
limited market release, we never would have felt safe and secure
enough to ask our cast and crew to come back to set.”
Dr. Oscar San Román Orozco, MD, COVID-19 Clinic, University
Health System, Universidad Autonoma de Queretaro, Mexico,
explained, “Public Health interventions never work in silos,
because pandemics don’t just affect one sector. To overcome the
challenges that COVID-19 has given us, we need a robust systematic
approach that involves intersectoral, evidence-based interventions
and technology. Masimo SafetyNet-OPEN provides employers and
university leaders with the necessary tools to make their
communities feel safe through an organized, controlled, and
monitored strategy. We might not eradicate the disease soon, but we
can control it by segmenting work and social groups based on their
risk, monitoring these social bubbles using a robust screening and
contact tracing method, and trusting in new intersectoral
approaches and technologies. These will allow us to delimit the
viral propagation and maintain tight control in case any individual
gets infected.”
Joe Kiani, Founder and CEO of Masimo, said, “As the COVID-19
pandemic continues, organizations around the world are struggling
with the immense challenge of balancing the health and safety of
employees, students, and members with the economic and educational
needs of their communities. Masimo has developed numerous
technologies to help patients and clinicians stay safe during the
pandemic. With SafetyNet-OPEN, we’ve combined our decades of
expertise in patient monitoring with our latest innovations in
automation and connectivity to help organizations confront this
challenge and better manage future ones.”
@Masimo | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. Our mission is to improve patient outcomes and reduce
the cost of care. Masimo SET® Measure-through Motion and Low
Perfusion™ pulse oximetry, introduced in 1995, has been shown in
over 100 independent and objective studies to outperform other
pulse oximetry technologies.2 Masimo SET® has also been shown to
help clinicians reduce severe retinopathy of prematurity in
neonates,3 improve CCHD screening in newborns,4 and, when used for
continuous monitoring with Masimo Patient SafetyNet™ in
post-surgical wards, reduce rapid response team activations, ICU
transfers, and costs.5-8 Masimo SET® is estimated to be used on
more than 200 million patients in leading hospitals and other
healthcare settings around the world,1 and is the primary pulse
oximetry at 9 of the top 10 hospitals according to the 2020-21 U.S.
News and World Report Best Hospitals Honor Roll.9 Masimo continues
to refine SET® and in 2018, announced that SpO2 accuracy on RD SET®
sensors during conditions of motion has been significantly
improved, providing clinicians with even greater confidence that
the SpO2 values they rely on accurately reflect a patient’s
physiological status. In 2005, Masimo introduced rainbow® Pulse
CO-Oximetry technology, allowing noninvasive and continuous
monitoring of blood constituents that previously could only be
measured invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®),
Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen
Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient
Monitoring and Connectivity Platform, built from the ground up to
be as flexible and expandable as possible to facilitate the
addition of other Masimo and third-party monitoring technologies;
key Masimo additions include Next Generation SedLine® Brain
Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography
with NomoLine® sampling lines. Masimo’s family of continuous and
spot-check monitoring Pulse CO-Oximeters® includes devices designed
for use in a variety of clinical and non-clinical scenarios,
including tetherless, wearable technology, such as Radius-7® and
Radius PPG™, portable devices like Rad-67™, fingertip pulse
oximeters like MightySat® Rx, and devices available for use both in
the hospital and at home, such as Rad-97®. Masimo hospital
automation and connectivity solutions are centered around the
Masimo Hospital Automation™ platform, and include Iris Gateway®,
Patient SafetyNet, Replica™, Halo ION™, UniView™, UniView: 60™, and
Masimo SafetyNet™. Additional information about Masimo and its
products may be found at www.masimo.com. Published clinical studies
on Masimo products can be found at
www.masimo.com/evidence/featured-studies/feature/.
ORi and RPVi have not received FDA 510(k) clearance and are not
available for sale in the United States. The use of the trademark
Patient SafetyNet is under license from University HealthSystem
Consortium.
References
- Estimate: Masimo data on file.
- Published clinical studies on pulse oximetry and the benefits
of Masimo SET® can be found on our website at
http://www.masimo.com. Comparative studies include independent and
objective studies which are comprised of abstracts presented at
scientific meetings and peer-reviewed journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on
the detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
- Taenzer A et al. Impact of pulse oximetry surveillance on
rescue events and intensive care unit transfers: a before-and-after
concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth
Experience. Anesthesia Patient Safety Foundation Newsletter.
Spring-Summer 2012.
- McGrath S et al. Surveillance Monitoring Management for General
Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With
Sedative and Analgesic Medications: Impact of Continuous Monitoring
on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14
Mar. DOI: 10.1097/PTS.0000000000000696.
-
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential effectiveness of SafetyNet-OPEN™, Radius
Tº™, and Radius PPG™. These forward-looking statements are based on
current expectations about future events affecting us and are
subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause
our actual results to differ materially and adversely from those
expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo's unique noninvasive measurement
technologies, including Masimo SafetyNet-OPEN, Radius Tº, and
Radius PPG, contribute to positive clinical outcomes and patient
safety; risks related to our belief that Masimo noninvasive medical
breakthroughs provide cost-effective solutions and unique
advantages; risks related to COVID-19; as well as other factors
discussed in the "Risk Factors" section of our most recent reports
filed with the Securities and Exchange Commission ("SEC"), which
may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether
our expectations will prove correct. All forward-looking statements
included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of today's date. We do not undertake any
obligation to update, amend or clarify these statements or the
"Risk Factors" contained in our most recent reports filed with the
SEC, whether as a result of new information, future events or
otherwise, except as may be required under the applicable
securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210215005059/en/
Masimo Evan Lamb 949-396-3376 elamb@masimo.com
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Apr 2023 to Apr 2024